If you need more lookups,
subscriptions start at $34 USD/month.
Harry Miao Location
United States
Harry Miao Work
VP, Clinical Development @ (April 2021 - Present)
Executive Medical Director @ (January 2018 - April 2021)
Executive Director @ Epizyme (April 2016 - January 2018)
Executive Director @ (November 2014 - April 2016)
Director @ (August 2010 - November 2014)
Director, Clinical Development @ (February 2007 - August 2010)
Associate Director @ ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company (September 2000 - January 2007)
Harry Miao Education
Harvard University
Hebrew University of Jerusalem
Qingdao University
Harry Miao Skills
Oncology Clinical Research
Translational Medicine
Drug Development
Drug Discovery
Biotechnology
Biopharmaceuticals
Biomarkers
Pharmaceutical Industry
Clinical Pharmacology
Molecular & Cellular Biology
Antibodies
CRO
IND
Oncology
Small Molecules
GCP
Immunology
FDA
Clinical Research
Regulatory Submissions
Biochemistry
Molecular Biology
U.S. Food and Drug Administration (FDA)
Cell Biology
CRO Management
Technology Transfer
Cell
Clinical Development
Customer Service
Molecular and Cellular Biology
Development
CEP
Healthcare
Microsoft Excel
u.s. Food and Drug Administration Fda
u.s. Food and Drug Administration
Harry Miao Summary
Harry Miao, based in United States, is currently a VP, Clinical Development at Kite Pharma. Harry Miao brings experience from previous roles at Takeda Oncology, Epizyme, Incyte and Sanofi. Harry Miao holds a Harvard University. With a robust skill set that includes Oncology Clinical Research, Translational Medicine, Drug Development, Drug Discovery, Biotechnology and more. Harry Miao has 1 emails on RocketReach.
Looking for a different Harry Miao?
Find contact details for 700 million professionals.